Following the recent annoucement of AstraZeneca's positive results for Q1 of 2025, the company's CEO, Pascal Soriot, has suggested that the company is to further invest into its US pharmaceutical R&D and manufacturing capacity.
This decision follows the company's plans to pour $3.5bn into US R&D and manufacturing, which was announced in November 2024.
AstraZeneca is one of many pharma companies investing in its US production capacity following Trump's pharmaceutical tariff threats — with huge names such as Johnson & Johnson, Novartis, Eli Lilly, Roche and Thermo Fisher Scientific investing more than $100 billion into US production and research.
In a press statement, Soirot noted that AstraZeneca is "firmly committed to investing and growing in the US."
He also stated that the company is "continuing to benefit" from its "broad-based source of revenue and global manufacturing footprint — including eleven production sites in the US covering small molecules, biologics and cell therapies."
When discussing AstraZeneca's intentions to expand its US manufacturing capacity, he said that the company planned to leverage "two large R&D sites in Gaithersburg, Maryland and Cambridge, Massachusetts."
However, the company is also betting on China, with the company recently unveiling plans to invest $2.5bn into its R&D and manufacturing capacity within the country.